Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
about
First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemiaHow I treat acquired aplastic anemiaImmune Mechanisms in Myelodysplastic SyndromeMissing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in ChildhoodHaploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemiaNew directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunityEltrombopag in aplastic anemiaThe European Hematology Association Roadmap for European Hematology Research: a consensus documentImmunosuppressive therapy for transplant-ineligible aplastic anemia patients.Anti-thymocyte serum as part of an immunosuppressive regimen in treating haematological immune-mediated diseases in dogs.Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia.The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia.A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia.Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow TransplantationEltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.Recent advances in treatment of aplastic anemia.Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience.First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapyDiagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC)Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.Immune-mediated bone marrow failure in C57BL/6 miceActivity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaConditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donorModel-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.Graves disease following rabbit antithymocyte globulin treatment of severe aplastic anemia in a Korean child.In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.Eltrombopag and improved hematopoiesis in refractory aplastic anemia.Not all anti-T lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly inferior results with jurkat cell-reactive anti-T lymphocyte globulin in clinical practiceEvolving hematopoietic stem cell transplantation strategies in severe aplastic anemia.Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia.Anemia of Central Origin.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Acquired aplastic anemia in children.A plasma microRNA signature as a biomarker for acquired aplastic anemia.Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome
P2860
Q24201108-C5077549-CD5C-464D-83D2-58DC94056A05Q24617687-B0D263C3-30CC-49A2-9830-A307F3538D13Q26744500-F6B363AF-599D-4FA1-95C6-0330EF6CD79AQ26798389-06932993-0F24-46DA-B80D-DADAB6268864Q26799396-7A0B1794-BFBE-44C6-9751-522161CBBDA9Q26823090-477576BB-8F1A-4D28-A46C-AE711B9145E1Q28085299-89001E48-AEDE-4795-B950-78937C0CDEC9Q28830861-86E755B1-ADD9-4BD6-9AA1-A8F39FAACAC6Q33419679-179A8928-5D3F-4DEC-8D2B-6ED37118FE1FQ33440630-9AA6264E-D579-4C45-A929-E384DC2D7B4FQ33757965-73EA64CB-B958-4FD9-9FAD-1FD4BD7B6CE3Q33797194-0AAE3CBA-55D2-472F-95D5-8C94D609B740Q33820120-47DA1987-E1A3-4A1C-ABFA-072E5C859CDDQ33828560-A82C6CE3-0215-452E-87B0-2025232F3355Q34269519-78B5D296-D59F-435C-BA29-CC0733FF767CQ34272519-2CEE71EE-E533-4C2C-945F-4217AE35A1BAQ34392449-A3FF15E9-FC24-4019-9E02-4E220F165BDCQ34431435-B3B32B47-13B7-433F-9EA5-8D78BB7B01E0Q34451351-59319BD0-6DC1-4356-B518-5D17C6697941Q34555435-28C159A8-C05A-4523-8C89-F4226DF529F3Q34647767-DF7C092B-AA84-457C-A80C-D63DBC5EA192Q34649082-2B902514-19B4-4B8F-B71F-7FFD725E7DF0Q34790303-E5641952-3408-4AFF-B53F-7F74105D9AC0Q35220764-145C267D-A3FB-4EB6-825E-3197A6C677FFQ35230019-4DAB0890-6555-4148-B381-ECD6D618F655Q35669193-2B4D184D-B802-4783-8201-9FEEB0A6E1ECQ35805248-C5EEC1AB-DFD9-4801-BDDC-4FC5185A53BFQ35967925-E8F2B3AC-C98B-46AA-A320-BACF7173125BQ35976451-51F5873C-1D78-4109-B408-22E8887178D0Q36036288-DC136952-F4A5-4C9E-ABB7-C81B994D3963Q36174878-98EDA8F1-F0E9-4F5E-AD62-BA7C1A209A8BQ36317960-7B6E73E2-FBAB-42BA-A8EC-3FC72FAD3AA3Q36497220-C9ED6162-A6B3-4427-A21F-54926D488225Q36553599-D186D242-5576-4545-8684-085B131CF6A9Q36784115-10A34CD0-3753-493E-B632-78FDE6D413D9Q36980277-A300C087-D7E6-42C3-A403-C139A641797DQ37490754-FED9AE6F-D320-4920-B783-BB9863291EFCQ37555805-FF8A0A81-CD9B-4AF6-82EA-149DC89E3795Q37580829-F5405028-7636-4795-95EB-3CC15425C06EQ37584833-3D95758A-E4AD-499B-84FF-FF022B8EA3DF
P2860
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
@en
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.
@nl
type
label
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
@en
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.
@nl
prefLabel
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
@en
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.
@nl
P2093
P2860
P356
P1476
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
@en
P2093
Angélique Biancotto
Barbara Weinstein
Colin O Wu
Neal S Young
Olga Nunez
Phillip Scheinberg
Priscila Scheinberg
P2860
P304
P356
10.1056/NEJMOA1103975
P407
P577
2011-08-01T00:00:00Z